RecruitingNCT04328298

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)


Sponsor

The Lymphoma Academic Research Organisation

Enrollment

5,000 participants

Start Date

Dec 19, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a registry including prospective and retrospective data on all patients who have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell treatment.


Eligibility

Min Age: 0 YearsMax Age: 99 Years

Inclusion Criteria8

  • Retrospective inclusion :
  • Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center
  • If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive
  • Prospective inclusion :
  • Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center.
  • Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019
  • Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019
  • If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(36)

CHU d'Amiens - Hôpital Sud

Amiens, France

CHU Angers

Angers, France

CHRU Besançon - Hôpital Minjoz

Besançon, France

CHU de Brest - Hôpital du Morvan

Brest, France

Institut d'Hématologie de Basse Normandie

Caen, France

CHU d'Estaing

Clermont-Ferrand, France

APHP - Hôpital Henri Mondor

Créteil, France

CHU de Dijon

Dijon, France

CHU de Grenoble

La Tronche, France

CHRU de Lille - Hôpital Claude Hurriez

Lille, France

Hôpital Dupuytren

Limoges, France

Centre Léon Bérard

Lyon, France

Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)

Lyon, France

Hôpital de la Timone

Marseille, France

Institut Paoli Calmette

Marseille, France

CHU de Montpellier

Montpellier, France

CHU de Nantes - Hôtel Dieu

Nantes, France

CHU de Nice

Nice, France

APHP - Hôpital Cochin

Paris, France

APHP - Hôpital La Pitié Salpêtrière

Paris, France

APHP - Hôpital Necker

Paris, France

APHP - Hôpital Saint Antoine

Paris, France

APHP - Hôpital Saint Louis

Paris, France

APHP - Hôpital Universitaire Robert Debré

Paris, France

Centre Francois Magendie

Pessac, France

Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Hôpital de la Milétrie - CHU de Poitiers

Poitiers, France

CHU de Rennes - Hôpital Pontchaillou

Rennes, France

Centre Henri Becquerel

Rouen, France

CHU de Rouen Normandie

Rouen, France

Institut de Cancérologie Hématologie Universitaire de Saint Etienne

Saint-Priest-en-Jarez, France

ICANS (Institut de Cancérologie Strasbourg Europe)

Strasbourg, France

Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)

Toulouse, France

CHU Bretonneau

Tours, France

CHU Brabois

Vandœuvre-lès-Nancy, France

Gustave Roussy Cancer Campus

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04328298